Massimilano Colao Net Worth

The estimated Net Worth of Massimilano Colao is at least $127 mil dollars as of 2 March 2022. Massimilano Colao owns over 3,205 units of Aurinia Pharmaceuticals Inc stock worth over $88,122 and over the last 3 years Massimilano sold AUPH stock worth over $38,492.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Massimilano Colao AUPH stock SEC Form 4 insiders trading

Massimilano has made over 1 trades of the Aurinia Pharmaceuticals Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Massimilano sold 3,205 units of AUPH stock worth $38,492 on 2 March 2022.

The largest trade Massimilano's ever made was selling 3,205 units of Aurinia Pharmaceuticals Inc stock on 2 March 2022 worth over $38,492. On average, Massimilano trades about 3,205 units every 0 days since 2022. As of 2 March 2022 Massimilano still owns at least 13,495 units of Aurinia Pharmaceuticals Inc stock.

You can see the complete history of Massimilano Colao stock trades at the bottom of the page.

What's Massimilano Colao's mailing address?

Massimilano's mailing address filed with the SEC is #1203-4464 MARKHAM STREET, , VICTORIA, A1, V8Z7X8.

Insiders trading at Aurinia Pharmaceuticals Inc

Over the last 4 years, insiders at Aurinia Pharmaceuticals Inc have traded over $22,019,765 worth of Aurinia Pharmaceuticals Inc stock and bought 107,125 units worth $893,295 . The most active insiders traders include Timothy P Walbert, Michael R Hayden, eMichael Robert Martin. On average, Aurinia Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of $193,451. The most recent stock trade was executed by Scott Michael Habig on 6 August 2024, trading 18,249 units of AUPH stock currently worth $96,902.

What does Aurinia Pharmaceuticals Inc do?

aurinia pharmaceuticals is a biotechnology company located in 5120-75 street, edmonton, canada.

Complete history of Massimilano Colao stock trades at Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc executives and stock owners

Aurinia Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Peter Greenleaf,
  President, Chief Executive Officer, Director
• Peter S. Greenleaf M.B.A.,
  Pres, CEO & Director
• Maxwell Donley,
  Executive Vice President, Internal Operations & Strategy
• Neil Solomons,
  Chief Marketing Officer
• Massimiliano Colao,
  Chief Commercial Officer
• Robert Huizinga,
  Executive Vice President - Corporate Development
• Matthew Maxwell Donley M.B.A.,
  Exec. VP of Operations & Strategy
• Joseph M. Miller CPA,
  Chief Financial Officer
• Dennis Bourgeault,
  Chief Financial Officer
• Michael Martin,
  Chief Operating Officer
• Daniel Billen,
  Director
• George Milne,
  Independent Chairman of the Board
• Michael Hayden,
  Independent Director
• Stephen P. Robertson,
  Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Joseph Hagan,
  Independent Director
• David Jayne,
  Independent Director
• R. Hector MacKay-Dunn,
  Director
• Jill Leversage,
  Independent Director
• Stephen Robertson,
  Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
• Timothy Walbert,
  Independent Director
• Max Colao,
  Chief Commercial Officer
• Tim Hermes,
  Vice President of Market Access
• Cara Felish,
  Vice President of Commercial Operations
• Chris Hays,
  Vice President of Marketing
• Fran Lynch,
  Vice President of Sales
• Glenn Schulman,
  Senior Vice President - Corporate Communications and Investor Relations
• Michael R. Martin,
  Chief Bus. Officer
• Dr. Robert B. Huizinga M.Sc., Ph.D., R.N., RN NNC, MSc(Epi), CNeph(C),
  Exec. VP of Research
• Scott Michael Habig,
  Chief Commercial Officer
• Volker Knappertz,
  EVP, Research and Development
• Joseph M Miller,
  Chief Financial Officer
• Brinda Balakrishnan,
  Director
• Robert T Foster,
  Director
• Massimilano Colao,
  Chief Commercial Officer
• Jeffrey Allen Bailey,
  Director
• Karen L. Smith,
  Director